FeesSafety
Pluang+

UMH Properties posts 7% EBITDA growth with strong preferred dividend yield at 7.7%.

Company Fundamentals
08 Nov 2026, 17:35 WIB
Seeking Alpha
View Source
Bullish
UMH Properties posts 7% EBITDA growth with strong preferred dividend yield at 7.7%.

UMH Properties, a REIT managing 145 manufactured home communities, reported a 7% year-over-year increase in adjusted EBITDA for Q3, reflecting solid financial performance. The company maintains manageable interest expenses by refinancing old debt at low rates around 6% and prioritizing a low-cost line of credit for capital needs. Its Series D preferred shares offer an attractive 7.7% stripped yield, supported by real estate assets and a strong equity cushion, making the preferred shares a favorable risk/reward investment. However, the analyst remains cautious on UMH common shares, which trade at a premium valuation of 13–13.5 times next year's consensus FFO.

UMH Properties preferred stock yield context is provided here with Pluang's Real Estate sector data as of Nov 08, 2026 21:11 WIB. For readers following Real Estate, of 47 priced US stocks on Pluang, 17 rose and 30 fell today. Notable movers include AHR at USD 57.91 with a +3.34% change and a typical hold time of 15 days, WY at USD 20.98 down -3.01% with a 1-day hold, and CTRE at USD 38.21 up +2.77% with a 24-day hold.

More News

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Velinotamig shows strong safety and efficacy in treating refractory systemic lupus erythematosus, with notable kidney improvements.

Cullinan Therapeutics announced promising Phase 1b/2a trial results for velinotamig, a BCMAxCD3 T cell engager, in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE). Among nine evaluable patients, eight showed significant...

Market News
Bullish
35 minutes ago
CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics reports positive Phase 1 results for zugo-cel in treating refractory autoimmune diseases.

CRISPR Therapeutics announced encouraging Phase 1 trial results for zugo-cel, their gene-edited CAR-T cell therapy targeting refractory autoimmune diseases like systemic sclerosis, lupus, and idiopathic inflammatory myopathy. Among 21 patients treate...

Market News
Bullish
35 minutes ago
Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

Colin Kaepernick named Humanitarian of the Year at 2026 Muhammad Ali Humanitarian Awards.

At the 13th annual Muhammad Ali Humanitarian Awards in Louisville, Colin Kaepernick was honored as Humanitarian of the Year for his activism and entrepreneurship, including founding literacy platform Lumi and Know Your Rights Camp. The event also rec...

Others
Neutral
1 hour ago
New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

New Phase 1/2 data show Cabaletta's rese-cel therapy offers durable, immunomodulator-free benefits in autoimmune diseases.

Cabaletta Bio announced Phase 1/2 clinical data for rese-cel, a CAR T cell therapy targeting autoimmune diseases, showing durable benefits without immunomodulators across dermatomyositis, lupus nephritis, and systemic sclerosis patients. All dermatom...

Market News
Bullish
1 hour ago
Ripple and Privy launch embedded XRP Ledger wallets as whales accumulate 16.46M XRP amid price volatility

Ripple and Privy launch embedded XRP Ledger wallets as whales accumulate 16.46M XRP amid price volatility

Ripple has partnered with Stripe-owned Privy to introduce embedded wallets on the XRP Ledger, enabling developers to build payment apps supporting XRP, RLUSD, and other assets. This integration allows automated transactions and easier wallet manageme...

Protocol Fundamentals
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App